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Abstract

The second-generation of direct-acting antiviral agents are the current treatment for
chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients
receiving this therapy, liver biopsy remains the most accurate method, but the invasiveness
of this procedure is its major drawback. Different non-invasive tests have been used to
study changes in the stage of liver fibrosis in patients with chronic viral hepatitis treated
with the second-generation of direct-acting antiviral agents: liver stiffness measurements
(with transient elastography or acoustic radiation force impulse elastography) or different
scores that use serum markers to calculate a fibrosis score. We prepared a literature review
of the available data regarding the long-term evolution of liver fibrosis after the treatment
with direct-acting antiviral agents for chronic viral hepatitis C.
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Highlights

✓ Transient elastography is the routine investigation for liver fibrosis monitoring in patients
with chronic viral hepatitis C treated with direct acting antiviral agents.

chronic viral hepatitis C, direct-acting antiviral agents, liver fibrosis

✓ The APRI and FIB-4 scores registered the highest decrease between the baseline and the
end of the treatment in patients with chronic viral hepatitis C treated with direct acting
antiviral agents.
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Introduction
The main objective in treating chronic viral hepatitis C
(CHC) with the second-generation of direct-acting
antiviral agents (DAAs) is to achieve a sustained virologic
response (SVR). Reversing liver fibrosis in previously
infected patients is a secondary goal, since achieving viral
clearance does not reverse all the liver damage. DAAs do
not have an anti-fibrotic effect (1). In patients who
achieved SVR with interferon therapy (the previous
standard of care in CHC), liver fibrosis regression was
measured in 42% of the cases, while 53.1% of the patients
did not have a significant change in the liver fibrosis stage,
and fibrosis progression was reported in 4.6% of the
patients (2).
In order to measure liver fibrosis, besides the gold
standard of liver biopsy, various fibrosis scores calculated
from routine laboratory tests have been developed and
validated in recent years. These scores have numerous
advantages, as they are neither invasive procedures nor
expensive investigations. The aim of this article is to assess
the changes that occur in liver fibrosis after SVR is
achieved with DAAs, measured through liver biopsy and
different non-invasive tests: transient elastography (TE),
acoustic radiation force impulse elastography (ARFI),
fibrosis-4 score (FIB-4), aspartate aminotransferaseplatelet ratio index (APRI), and hyaluronic acid (HA).

Discussions
Transient Elastography (TE)
TE represents a non-invasive method of liver stiffness
(LS) measurement which is used for fibrosis screening in
various hepatic disorders as an alternative to liver biopsy
(3). TE is routinely performed for liver fibrosis assessment
prior to DAA therapy and also as a follow-up after
achieving SVR (4-6).
A cohort study including adults with CHC who
received DAA-based therapies reports a regression of
>30% in LS measured by TE 12 months after the end of
treatment (EOT) (7). Fibrosis regression was demonstrated
in another study including patients with advanced fibrosis
(F3-F4), who were monitored by TE at baseline, at EOT,
and 12 weeks and 24 weeks after EOT (8). There were
significant differences registered by TE between the
baseline and EOT (8.3 kPa vs 7.4 kPa), EOT and 24-week
SVR (7.4 kPa vs 5.3 kPa), and baseline and 48-week SVR
(8.3 kPa vs 5.4 kPa) (9).
An improvement of LS was noticed in 82% of the
patients with SVR at a 2-year follow-up. In 42% of the
cases, liver fibrosis was decreased by at least 3 kPa (10).

Facciorusso et al. found an LS decrease from 12.3 kPa to
6.6 kPa at a 5-year follow-up after DAA therapy (11).
Another study with a long follow-up period (up to 72
weeks after EOT) indicated a significant and steady decline
in LS values. The median LS values were 11.25 kPa before
the initiation of treatment, 7.8 kPa at EOT, 6.45 kPA at 24
weeks of SVR, 6.25 kPa at 48 weeks of SVR, and 5.45 kPa
at 72 weeks of SVR (12). In patients with liver cirrhosis, a
large decrease in LS was observed, from a 32.5 kPa median
at baseline to a 21.3 kPa median at EOT (13).
APRI
APRI is a simple-to-use liver fibrosis marker,
calculated by applying the following formula: [Aspartate
aminotransferase level (ULN)/platelet count (109/L)] ∗100
(14). The APRI test has a 65.1% sensitivity (Se) and 7l.8%
specificity (Sp) in detecting F2-F3, and 93.8% Se and
72.4% Sp in diagnosing liver cirrhosis. An APRI value of
0.77 differentiates F1 and F2, and a value of 0.84 is the cutoff between F3 and F4 (14, 15). APRI values decrease in
CHC patients after treatment with DAAs, even in subjects
who do not achieve SVR. In patients with SVR, the median
APRI was lowered from 1.07 to 0.41. In non-SVR patients,
the median value dropped from 2.05 to 1.13 (5). In another
study, 48% of the patients had an APRI score higher than
1 at baseline, but after DAA treatment, only 7.7% had
APRI values above 1 (16).
Median APRI values decrease significantly after 24
weeks of DAA therapy, from 1.4 to 0.5. After this period,
the APRI stabilizes, and at 96 weeks after EOT no
significant change is observed (17). Lledó et al. reported
that the APRI index was decreased at EOT, but there was
no significant variation in its values at 12-week SVR
follow-up: 1.47 at baseline, 0.58 at EOT, and 0.54 at SVR
(18). APRI regression is found in patients with liver
transplant treated with DAAs (from 2.7±0.3 to 0.4±0.05 at
12-week SVR). Patients with severe inflammation or liver
steatosis at baseline have greater improvements in the
APRI index compared to those with lower inflammation
and no steatosis (19). In the study conducted by Fabbri et
al., APRI decreased in hepatitis C/HIV co-infected patients
who underwent treatment with DAAs from a median of
0.94 to 0.37 (20).
Improvements in the APRI score after CHC treatment
are explained by the normalization of liver enzymes and
the increase in the number of platelets. Patients with F2-F3
have an improvement in APRI regardless of their treatment
response. In patients with cirrhosis, fibrosis regression is
significantly correlated with achieving SVR (21). In a
study by Christian et al., the reduction in APRI was found
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to be more pronounced in patients with F0-F2 compared to
F3-F4 (22).
Tao et al. studied liver fibrosis regression in CHC
patients infected with the genotype 3 variant of hepatitis C
virus, treated with 3 different DAA regimens. This
particular viral genotype has a faster progression of liver
fibrosis to cirrhosis and shows more resistance to DAAs. A
significant reduction in APRI was found after different
DAA treatments, both in respondents (from 1.834 to 0.619,
p < 0.001) and non-respondents (from 5.026 to 1.248,
p = 0.002 for relapsed patients) (23).
Serum markers of liver fibrosis
Different serum biomarkers have been studied for the
detection of liver fibrosis.
Hyaluronic acid (HA) was demonstrated to be useful
for the detection of liver fibrosis in CHC patients,
especially in cases where liver biopsy is restricted (such as
end-stage renal disease) (24, 25). CHC patients who
responded to treatment with daclatasvir and asunaprevir
had a lower value of HA at SVR compared to the baseline
values (123 ± 43 vs. 71 ± 14 ng/mL, p<0.01), while nonrespondents showed no significant difference before and
after the treatment (145 ± 43 vs. 172 ± 46 ng/mL, p =
0.465) (26). The Enhanced Liver Fibrosis (ELF) score is an
algorithm that uses age and serum levels of procollagen
type III amino terminal propeptide, tissue inhibitor of
metalloproteinases-1 and HA to give an estimate for liver
fibrosis. In a sofosbuvir treatment study, the ELF score was
decreased compared to the baseline (from 10.00 to 9.37,
p=0.007). Patients treated with sofosbuvir and pegylated
interferon showed a temporary increase in HA
measurements at 4 weeks during the treatment (from 59.5
to 177.9 mg/ml, p=0.002), presumably because of the proinflammatory effect associated with the interferon therapy
(6).
FIB-4
The FIB-4 score has been established alongside other
non-invasive fibrosis scores in the international guidelines
for the evaluation of liver fibrosis (15). The Apricot study
developed a simple test using laboratory measurements to
predict liver fibrosis in a large cohort of HIV/hepatitis C
co-infected patients. The results of the study showed that
age, serum aspartate aminotransferase, international
normalized ratio, and platelet count were independent
predictors of fibrosis. These variables were used to obtain
the following formula: Age (years) × aspartate
aminotransferase [U/L] / (platelets [109/L] × (alanine
aminotransferase [U/L])1/2), known today as the FIB‐4
index (27). In a recent study on a multicenter real-world
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cohort, significant liver fibrosis and cirrhosis were
predicted with high accuracy by FIB-4 using TE as a
reference (28).
FIB-4 has been validated for the evaluation of CHC and
has acceptable Se and Sp, particularly in advanced fibrosis
and cirrhosis. FIB-4 shows a significant decrease in all
patients undergoing DAA treatment, especially in those
achieving SVR (p<0.001) (5). A significant decline in FIB4 values is seen from baseline to 24 weeks after SVR
(p<0.0001) (11).
Another study proposed that a longer follow‐up period
could allow detection of LS changes unrelated to the
decrease in the liver inflammatory activity, but rather
associated with the improvement in liver architecture and
function. Giannini et al. followed up 52 CHC patients for a
median of 60 weeks after successful DAA treatment with
SVR. FIB‐4 values progressively decreased from baseline
to the end of the follow‐up period (16).
ARFI
ARFI is a novel procedure that enables the assessment
of liver fibrosis during a conventional ultra-sonographic
examination. This imaging technique quantifies the
mechanical properties of tissues, without manual
compression, by measuring the shear wave velocity
induced by acoustic radiation and propagation in the liver
tissue (29). Compared to TE, the elastography technique
currently used in clinical practice, ARFI showed promising
results in the assessment of liver fibrosis staging in CHC
and HIV/hepatitis C co-infected patients (13, 30). Similar
to other studies on patients with SVR after DAAs, the
ARFI evaluation found that LS improves in patients with
cirrhosis. Also, a decrease in LS was detected at 24 weeks
after SVR by ARFI similar to TE (from 2.04 ± 0.62 m/s at
baseline to 1.75 ± 0.57 m/s at 24 weeks after SVR) (31).
Liver biopsy
The degree of inflammation, the stage of fibrosis, and
the histological improvement after achieving SVR are still
best evaluated through liver biopsy (32). In addition to
these findings, a recent short-term study evaluated 51
patients who underwent liver biopsies after SVR was
achieved. Although liver enzymes normalized after
achieving SVR, significant histological inflammation was
still present in 16% of the patients (33).
Jason et al. tried to assess whether TE can be used in
the management of patients with advanced fibrosis or
cirrhosis, after achieving SVR, and compared the results to
liver biopsy. In their study, there was discordance between
post-SVR fibrosis stages predicted by TE vs. liver biopsy.
Thus, it is unclear if TE following SVR can predict the
fibrosis stage as reliably as liver biopsy (34).

Olga Hilda Orasan et al.

Conclusions
TE has become a routine investigation for liver fibrosis
monitoring in patients receiving treatment with DAAs,
ARFI being another elastography method that can be used.
The APRI and FIB-4 scores registered the greatest change
when measured at EOT, since the platelet count and the
liver aminotransferase values that make up their formulas
showed the most significant improvement around that
point. Serum markers such as HA, tissue inhibitor of
metalloproteinases-1, and the combined ELF score also
improve after the treatment with DAAs.

Acronyms and abbreviations
APRI – aspartate aminotransferase-platelet ratio index
ARFI – acoustic radiation force impulse elastography
CHC – chronic viral hepatitis C
DAAs – direct-acting antiviral agents
EOT – end of treatment
FIB-4 – fibrosis-4 score
HA – hyaluronic acid
LS – liver stiffness
Se – sensitivity
Sp – specificity
SVR – sustained virologic response
TE – transient elastography.
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